<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25085">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939314</url>
  </required_header>
  <id_info>
    <org_study_id>TX 360 HA -Schaffer</org_study_id>
    <secondary_id>Tian Medical Inc.</secondary_id>
    <nct_id>NCT01939314</nct_id>
  </id_info>
  <brief_title>Sphenopalatine Nerve Block for Headache TX 360</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind Study Comparing the Efficacy of Sphenopalatine Nerve Block by Localized Mucosal Application of an Anesthetic vs Placebo for the Emergency Department Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of shenopalatine nerve block
      utilizing the Tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the
      duration of the analgesia.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain Score</measure>
    <time_frame>up to 15 minutes from dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subsequent pain scores using the visual, horizontal, analog scales and pain relief score using a categorical scale will be performed at 5 minutes and 15 minutes after the dosing of treatment drug or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief</measure>
    <time_frame>up to 15 mins from dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following treatment, patients will  be asked to assess the amount of pain relief they experienced using a categorical score at 5 and 15 minutes for a total of two evaluations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Headache</condition>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivicaine .03ml to each nare</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline .03 ml to each nare</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>intervention</description>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  are 18 - 65 years of age

          -  present to ED triage with chief complaint of crescendo-onset anterior/frontal
             headache (affecting frontal, temporal, orbital, maxillary, and mandible region)

          -  have a normal neurological exams

        Exclusion Criteria:

          -  are less than 18 years old or greater than 65

          -  have any focal neurological dysfunction signs or symptoms

          -  have a posterior/occipital/cervicogenic source predominance of headache

          -  are febrile (oral temperature 37.7 C or 100 F) or signs of acute or chronic
             sinusitis, such as congestion, has been present more than 10 days, there is a high
             fever, the nasal mucus is an abnormal color, or complains of face pain or headaches

          -  have self treated with pain medication or anti-emetic 4 hours prior to arrival

          -  have a history of peripheral vascular disease, cancer, or HIV infection

          -  are known to be pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason T Schaffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 5, 2013</lastchanged_date>
  <firstreceived_date>September 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Terry Barclay</investigator_full_name>
    <investigator_title>Research Project Manager</investigator_title>
  </responsible_party>
  <keyword>Headache</keyword>
  <keyword>Migraine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
